Mr. Orlando has served as the Senior Vice President, Commercial New Product Planning since March 2022, previously serving as Vice President since joining Gossamer Bio in October 2018. Prior to joining Gossamer Bio, he was Vice President, Commercial Planning at Receptos from January 2015 to August 2015. After Receptos was acquired by Celgene in August 2015, Mr. Orlando continued in his role as Vice President, Commercial Planning, contributing to the pre-launch planning of ozanimod (Zeposia) in multiple sclerosis, until June 2018. Before joining Receptos, Mr. Orlando served as Senior Vice President, Corporate Planning & Development at Ambit Biosciences, a company focused on developing quizartinib, a FLT-3 inhibitor for the treatment of acute myeloid leukemia. He held that position from May 2013 until Ambit’s acquisition by Daiichi Sankyo in November 2014. Prior to Ambit, Mr. Orlando held the position of Vice President, Marketing at Neuromed Pharmaceuticals, a company focused on pain therapeutics. He led the commercial diligence effort to successfully out-license their phase 3 asset, Exalgo® (long-acting form of hydromorphone) to Covidien. Prior to Neuromed, Mr. Orlando held several senior commercial leadership roles, covering various therapeutic areas, in the USA, Canada and Europe with established firms including Wyeth, Genentech, GSK, and Eli Lilly. Mr. Orlando received an Honors B.Sc. from the University of Western Ontario in London, Ontario Canada.